Cannabinoide Arzneimittel bei Krebspatient*innen

Zusammenfassung

Medikamente, die die therapeutisch relevanten Inhaltsstoffe des Cannabis, Tetrahydrocannabinol (THC) und Cannabidiol (CBD), enthalten, kommen bei Krebspatient*innen zum Einsatz, um zum Beispiel Krankheitssymptome wie Schmerzen oder Nebenwirkungen der Therapien zu lindern sowie die Lebensqualität zu verbessern. Die Studienlage rechtfertigt die Anwendung von cannabinoiden Arzneimitteln als Add-on-Therapie bei einem Total-Pain-Syndrom sowie Übelkeit, Appetitlosigkeit, Schlaflosigkeit, erhöhtem Muskeltonus, Stress, depressiven Verstimmungen, Ängstlichkeit und fehlender Distanzierung zum Krankheitsgeschehen. Erste Hinweise deuten zudem auf eine mögliche Anti-Tumor-Wirkung dieser Arzneimittel hin.

Abstract

Medications containing the therapeutically relevant ingredients of cannabis, tetrahydrocannabinol (THC) and cannabidiol (CBD), are used in cancer patients, for example to alleviate symptoms such as pain or side effects of therapies and to improve quality of life. Research findings justify the use of cannabinoid medicines as an add-on therapy for total pain syndrome, nausea, loss of appetite, insomnia, increased muscle tone, stress, depressive moods, anxiety and lack of detachment from the disease. Initial indications also point to a possible anti-tumour effect of these drugs.

Schlüsselwörter

Krebs - Krebstherapie - Onkologie - Cannabis - THC - CBD

Key words

Cancercancer therapy - oncology - cannabis - THC - CBD

• Literatur

• 1 Abrams DI. Cannabis, Cannabinoids and cannabis-based medicines in cancer care. Integr Cancer Ther 2022; 21: 1-11
• 2 Bar-Lev Schleider L, Mechoulam R, Lederman V. et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 2018; 49: 37-43
• 3 Bar-Sela G, Cohen I, Campisi-Pinto S. et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel) 2020; 12: 2447
• 4 Böttge-Wolpers C, Bialas P, Gottschling S. et al Nutzen und Schaden von Cannabisarzneimitteln aus Sicht von Patienten mit chronischen Schmerzen und ihren Ärzten: Eine Kohortenstudie in drei saarländischen Schmerzzentren. Schmerz 2023; [online zuerst publiziert]
• 5 Bridgeman MB, Abazia DT. Medicinal cannabis: History. pharmacology, and implications for the acute care setting. PT 2017; 42: 180-188
• 6 Bundesinstitut für Arzneimittel und Medizinprodukte. Abschlussbericht der Begleiterhebung nach § 31 Absatz 6 des Fünften Buches Sozialgesetzbuch zur Verschreibung und Anwendung von Cannabisarzneimittel. Bonn: BfArM; 06.07.2022. Im Internet: https://www.bfarm.de/SharedDocs/Downloads/DE/Bundesopiumstelle/Cannabis/Abschlussbericht_Begleiterhebung.pdf?__blob=publicationFile; Stand: 01.02.2024
• 7 Christensen C, Allesø M, Rose M. et al. Clinical research evidence supporting administration and dosing recommendations of medicinal cannabis as analgesic in cancer patients. J Clin Med 2022; 12: 307
• 8 Grimison P, Mersiades A, Kirby A. et al. Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: A randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020; 31: 1553-1560
• 9 Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360
• 10 Hameed M, Prasad S, Jain E. et al. Medical cannabis for chronic nonmalignant pain management. Curr Pain Headache Rep 2023; 27: 57-63
• 11 Hasbi A, Madras BK, George SR. Endocannabinoid system and exogenous cannabinoids in depression and anxiety: A review. Brain Sci 2023; 13: 325
• 12 Herdegen T, Cascorbi I. Arzneimittelinteraktionen von THC und CBD in cannabinoiden Arzneimitteln (CAM): Empfehlungen für die Praxis. Dt Ärztebl 2023; 120: 833-840
• 13 Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol 2019; 176: 1384-1394
• 14 Hinz B, Ramer R. Cannabinoids as anticancer drugs: Current status of preclinical research. Br J Cancer 2022; 127: 1-13
• 15 Horlemann J, Schürmann N. DGS-Praxisleitlinie: Cannabis in der Schmerzmedizin. 2022 Im Internet https://dgs-praxisleitlinien.de/cannabis; Stand: 14.10.2023
• 16 Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007; 04: 1770-1804
• 17 Jatoi A, Windschitl HE, Loprinzi CL. et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-573
• 18 Kendall DA, Yudowski GA. Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front Cell Neurosci 2016; 10: 294
• 19 Kühne F, Becker LL, Bast T. et al. Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. Epilepsia Open 2023; 8: 360-370
• 20 Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018; 84: 2477-2482
• 21 Neumeister A, Normandin MD. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol Psychiatry 2013; 18: 1034-1040
• 22 Rahaman O, Ganguly D. Endocannabinoids in immune regulation and immunopathologies. Immunology 2021; 164: 242-252
• 23 Ramer R, Hinz B. Cannabinoids as anticancer drugs. Adv Pharmacol 2017; 80: 397-436
• 24 Ramer R, Wittig F, Hinz B. The endocannabinoid system as a pharmacological target for new cancer therapies. Cancers (Basel) 2021; 13: 5701
• 25 Schloss J, Lacey J, Sinclair J. et al. A phase 2 randomised clinical trial assessing the tolerability of two different ratios of medicinal cannabis in patients with high grade gliomas. Front Oncol 2021; 21: 649555
• 26 Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metab Rev 2014; 46: 86-95
• 27 Taylor L, Gidal B, Blakey G. et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2018; 32: 1053-1067
• 28 Twelves C, Sabel M, Checketts D. et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer 2021; 124: 1379-1387
• 29 Ueberall MA, Vila Silván C, Essner U. et al. Effectiveness, safety, and tolerability of nabiximols oromucosal spray vs typical oral long-acting opioid analgesics in patients with severe neuropathic back pain: Analysis of 6-month real-world data from the German pain e-registry. Pain Med 2022; 23: 745-760
• 30 Vučković S, Srebro D, Savić Vujović K. et al. Cannabinoids and pain: New insights from old molecules. Front Pharmacol 2018; 9: 1259
• 31 Waissengrin B, Mirelman D, Pelles S. et al. Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: A retrospective analysis. Ther Adv Med Oncol 2021; 13: 1758835921990203
• 32 Ward SJ, McAllister SD, Kawamura R. et al. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 2014; 171: 636-645
• 33 Wendelmuth C, Wirz S, Torontali M. et al. Dronabinol bei geriatrischen Schmerz- und Palliativpatienten: Eine retrospektive Auswertung der ambulanten kassenärztlichen Therapie. Schmerz 2019; 33: 384-391
• 34 Zikos TA, Nguyen L, Kamal A. et al. Marijuana, ondansetron, and promethazine are perceived as most effective treatments for gastrointestinal nausea. Dig Dis Sci 2020; 65: 3280-3286
• 35 Gastmeier K, Gastmeier A, Rottmann F. et al. Cannabinoide reduzieren den Opioidverbrauch bei älteren Schmerzpatienten: Eine retrospektive Dreijahresauswertung einer ambulanten kassenärztlichen Praxis. Schmerz 2023; 37: 29-37